Gene Transfer: Bax to the future for cancer therapy

Lemoine, N R; McNeish, I A
April 2004
Gut;Apr2004, Vol. 53 Issue 4, p478
Academic Journal
Malignant disease localized within the abdominal cavity has been a target for the staged development of clinical gene therapy approaches because of the smaller doses of experimental agent and increased safety margins over systemic administration. The article focuses on the Bax gene as a competitor in the marathon towards licensed cancer gene therapy. It supports the idea that apoptotic triggers will be useful in building cancer gene therapies of the future but it is clear that much effort is required for improved agent delivery and combinations with other therapeutic modalities to optimize their therapeutic effort.


Related Articles

  • Combining cellular and gene therapy approaches for treatment of intracranial tumors. Hickey, Michelle J.; Kasahara, Noriyuki; Mueller, Barbara M.; Kruse, Carol A. // OncoImmunology;Oct2013, Vol. 2 Issue 10, pe25989-1 

    New treatments are needed for brain metastasis, which is associated with high morbidity and mortality. Two novel cellular and gene therapy modalities were evaluated in xenograft models for human breast cancer. The individual and especially the combined treatments with alloreactive cytotoxic T...

  • Cancer Gene Therapy: The power of negative thinking. Lotze, M. T. // Gene Therapy;Feb2006, Vol. 13 Issue 3, p191 

    The article discusses the pathways for the gene therapy of cancer. The first pathway in gene therapy was discussed. The use of genetic constructs to confer novel properties of the cell, the second pathway, was described. The third pathway is to use nominally tumor-selective viruses that mediate...

  • Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels. Fonsatti, Ester; Altomonte, Maresa; Nicotra, Maria Rita; Natali, Pier Giorgio; Maio, Michele // Oncogene;9/29/2003 Review, Vol. 22 Issue 42, p6557 

    Among surface molecules expressed on endothelial cells, endoglin (CD105) is emerging as a prime vascular target for antiangiogenetic cancer therapy. CD105 is a cell membrane glycoprotein mainly expressed on endothelial cells and overexpressed on tumor-associated vascular endothelium, which...

  • Efficient and cancer-selective gene transfer to hepatocellular carcinoma in a rat using adenovirus vector with iodized oil esters. Shiba, Hiroaki; Okamoto, Tomoyoshi; Futagawa, Yasuro; Ohashi, Toya; Eto, Yoshikatsu // Cancer Gene Therapy;Oct2001, Vol. 8 Issue 10, p713 

    Gene therapy for cancer requires efficient, selective gene transfer to cancer cells. In gene therapy for hepatocellular carcinoma (HCC), gene transfer is efficient for small tumors, but not for large tumors. The delivery of anticancer agents and of iodized oil esters as embolic agents through...

  • Cancer gene therapy update. Smith, J.A.; Goldspiel, B.R. // Journal of Oncology Pharmacy Practice;Mar1999, Vol. 5 Issue 1, p7 

    Objective. To provide an update about gene marking and gene therapy trials in cancer patients. Data Sources. A MEDLINE search using the term “gene therapy” was conducted for the period 1985 to 1998. The reference lists from retrieved articles were reviewed. Meeting abstracts from the...

  • New therapies for non-muscle-invasive bladder cancer. Chiong, Edmund; Esuvaranathan, Kesavan // World Journal of Urology;Feb2010, Vol. 28 Issue 1, p71 

    The treatment of non-muscle-invasive bladder cancer (NMIBC) remains a challenge owing to its increased tendency to recur and the possibility of progression to potentially dangerous muscle-invasive disease. Treatment outcomes by current therapeutic modalities are still not optimal. In recent...

  • Gene transfer of interleukin 13 receptor α2 chain dramatically enhances the antitumor effect of IL-13 receptor–targeted cytotoxin in human prostate cancer xenografts. Kawakami, Koji; Husain, Syed R; Bright, Robert K; Puri, Raj K // Cancer Gene Therapy;Nov2001, Vol. 8 Issue 11, p861 

    IL-13Rα2 chain, the primary interleukin-13 (IL-13) binding protein, plays an important role in IL-13 binding and internalization. Based on these findings, in our previous study we transiently transfected four cancer cell lines that do not express IL-13Rα2 chain and demonstrated that these...

  • INGN 201: Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy — Introgen, RPR/INGN 201.  // BioDrugs;2003, Vol. 17 Issue 3, p216 

    Introgen's adenoviral p53 gene therapy [INGN 201, ADVEXIN[sup ®]] is in clinical development for the treatment of various cancers. The p53 tumour suppressor gene is deleted or mutated in many tumour cells and is one of the most frequently mutated genes in human tumours. INGN 201 has been...

  • A chimeric fusion of the hASH1 and EZH2 promoters mediates high and specific reporter and suicide gene expression and cytotoxicity in small cell lung cancer cells. Poulsen, T. T.; Pedersen, N.; Juel, H.; Poulsen, H. S. // Cancer Gene Therapy;Sep2008, Vol. 15 Issue 9, p563 

    Transcriptionally targeted gene therapy is a promising experimental modality for treatment of systemic malignancies such as small cell lung cancer (SCLC). We have identified the human achaete-scute homolog 1 (hASH1) and enhancer of zeste homolog 2 (EZH2) genes as highly upregulated in SCLC...


Read the Article


Sign out of this library

Other Topics